Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis

Trends in Molecular Medicine

Volumn 19, Issue 8, 2013, Pages 460-473

  Cao, Yihai ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Metastasis; PDGF; Targeted therapy; Tumor growth; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMATINIB; NESTIN; NITRIC OXIDE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR 2; VIMENTIN;

ASTROCYTE; BASEMENT MEMBRANE; CELL DENSITY; CELL MIGRATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; CONFORMATIONAL TRANSITION; DEREGULATION; DRUG RESISTANCE; EMBRYO DEVELOPMENT; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; GLIOBLASTOMA; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METASTASIS; MICROENVIRONMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; RADIOTHERAPY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TRANSACTIVATION; TRANSPLANTATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VASCULARIZATION;

EID: 84881023665     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.05.002     Document Type: Review

References (180)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
3. Nissen L.J., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117:2766-2777.
4. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999, 79:1283-1316.
5. Andrae J., et al. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
6. Hoch R.V., Soriano P. Roles of PDGF in animal development. Development 2003, 130:4769-4784.
7. Liu K.W., et al. Platelet-derived growth factor signaling in human malignancies. Chin. J. Cancer 2011, 30:581-584.
8. Heldin C.H., Westermark B. Platelet-derived growth factor: three isoforms and two receptor types. Trends Genet. 1989, 5:108-111.
9. Fambrough D., et al. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999, 97:727-741.
10. Nister M., et al. A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets. Cell 1988, 52:791-799.
11. Hamilton T.G., et al. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. Mol. Cell. Biol. 2003, 23:4013-4025.
12. Bostrom H., et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 1996, 85:863-873.
13. Lindahl P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
14. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 1994, 8:1888-1896.
15. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997, 124:2691-2700.
16. Klinghoffer R.A., et al. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol. Cell 2001, 7:343-354.
17. Ekman S., et al. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. Oncogene 1999, 18:2481-2488.
18. Heldin C.H., et al. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature 1986, 319:511-514.
19. Brockmann M.A., et al. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003, 52:1391-1399.
20. Beckmann M.P., et al. Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science 1988, 241:1346-1349.
21. Schmahl J., et al. PDGF signaling specificity is mediated through multiple immediate early genes. Nat. Genet. 2007, 39:52-60.
22. Hermanson M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992, 52:3213-3219.
23. Heinrich M.C., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
24. Sitaras N.M., et al. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res. 1988, 48:1930-1935.
25. McCarty M.F., et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest. 2007, 117:2114-2122.
26. Heldin C.H., Westermark B. PDGF-like growth factors in autocrine stimulation of growth. J. Cell. Physiol. Suppl. 1987, 5:31-34.
27. Jechlinger M., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 2006, 116:1561-1570.
28. Heldin C.H., Westermark B. Growth factors as transforming proteins. Eur. J. Biochem. 1989, 184:487-496.
29. Betsholtz C., et al. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:6440-6444.
30. Heldin C.H. Autocrine PDGF stimulation in malignancies. Ups. J. Med. Sci. 2012, 117:83-91.
31. Hellstrom M., et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
32. Bejcek B.E., et al. Transformation by v-sis occurs by an internal autoactivation mechanism. Science 1989, 245:1496-1499.
33. Keating M.T., Williams L.T. Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. Science 1988, 239:914-916.
34. LaRochelle W.J., et al. PDGF-D, a new protease-activated growth factor. Nat. Cell Biol. 2001, 3:517-521.
35. Bergsten E., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 2001, 3:512-516.
36. Li X., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat. Cell Biol. 2000, 2:302-309.
37. Simon M.P., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 1997, 15:95-98.
38. Sirvent N., et al. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003, 37:1-19.
39. Hermanson M., et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 1996, 56:164-171.
40. Liu K.W., et al. Platelet-derived growth factor receptor alpha in glioma: a bad seed. Chin. J. Cancer 2011, 30:590-602.
41. Lokker N.A., et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002, 62:3729-3735.
42. Hirota S., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660-667.
43. Maxwell M., et al. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. 1990, 86:131-140.
44. LaRochelle W.J., et al. Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res. 2002, 62:2468-2473.
45. Mapstone T., et al. Expression of platelet-derived growth factors, transforming growth factors, and the ros gene in a variety of primary human brain tumors. Neurosurgery 1991, 28:216-222.
46. Verhaak R.G., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
47. Nazarenko I., et al. Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. PLoS ONE 2011, 6:e18303.
48. Jackson E.L., et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006, 51:187-199.
49. Dai C., et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001, 15:1913-1925.
50. Assanah M., et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 2006, 26:6781-6790.
51. Shih A.H., Holland E.C. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006, 232:139-147.
52. Tchougounova E., et al. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 2007, 26:6289-6296.
53. Kim Y., et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 2012, 26:1247-1262.
54. Jiang Y., et al. PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 2011, 13:492-503.
55. Hambardzumyan D., et al. The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS ONE 2011, 6:e24454.
56. Hambardzumyan D., et al. Modeling adult gliomas using RCAS/t-va technology. Transl. Oncol. 2009, 2:89-95.
57. Lindberg N., et al. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 2009, 28:2266-2275.
58. Singh S.K., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
59. Holland E.C., et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998, 12:3675-3685.
60. Varela M., et al. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J. Surg. Oncol. 2004, 86:34-40.
61. Maher E.A., et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006, 66:11502-11513.
62. Network T.C.G.A. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
63. Ozawa T., et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010, 24:2205-2218.
64. Feng H., et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. J. Clin. Invest. 2011, 121:4670-4684.
65. Charles N., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6:141-152.
66. Pauls K., et al. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005, 46:166-175.
67. Roskoski R. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem. Biophys. Res. Commun. 2005, 337:1-13.
68. Kang H.J., et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005, 24:1066-1074.
69. Subramanian S., et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004, 23:7780-7790.
70. Ghanem M., et al. Expression and prognostic value of platelet-derived growth factor-AA and its receptor alpha in nephroblastoma. BJU Int. 2010, 106:1389-1393.
71. McDermott U., et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009, 69:3937-3946.
72. Yang J., et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010, 115:51-60.
73. Ross T.S., Gilliland D.G. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J. Biol. Chem. 1999, 274:22328-22336.
74. Golub T.R., et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
75. Magnusson M.K., et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001, 98:2518-2525.
76. Ustach C.V., et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res. 2010, 70:9631-9640.
77. Countaway J.L., et al. Reconstitution of epidermal growth factor receptor transmodulation by platelet-derived growth factor in Chinese hamster ovary cells. J. Biol. Chem. 1989, 264:13642-13647.
78. Decker S.J., Harris P. Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblasts. J. Biol. Chem. 1989, 264:9204-9209.
79. Walker F., Burgess A.W. Reconstitution of the high affinity epidermal growth factor receptor on cell-free membranes after transmodulation by platelet-derived growth factor. J. Biol. Chem. 1991, 266:2746-2752.
80. Li J., et al. Platelet-derived growth factor-stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation. J. Biol. Chem. 2000, 275:2951-2958.
81. Saito Y., et al. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 2001, 21:6387-6394.
82. Black P.C., et al. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J. Urol. 2011, 185:693-700.
83. Szerlip N.J., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3041-3046.
84. Faraone D., et al. Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 2006, 107:1896-1902.
85. Yeh C.Y., et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 2011, 11:139.
86. Kong D., et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26:1425-1435.
87. Patel P., et al. Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biol. 2010, 29:97-106.
88. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
89. Bruna A., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007, 11:147-160.
90. Petz M., et al. PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res. 2012, 40:9738-9749.
91. van Zijl F., et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033.
92. Fischer A.N., et al. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2007, 26:3395-3405.
93. Lahsnig C., et al. ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene 2009, 28:638-650.
94. Wang Z., et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim. Biophys. Acta 2010, 1806:122-130.
95. Kong D., et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
96. Gotzmann J., et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J. Cell Sci. 2002, 115:1189-1202.
97. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
98. Cao Y., et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 2011, 3:114rv113.
99. Hedlund E.M., et al. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17505-17510.
100. Kumar A., et al. Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation. J. Biol. Chem. 2010, 285:15500-15510.
101. Cao R., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 2002, 16:1575-1583.
102. Zhang J., et al. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2009, 23:153-163.
103. Lu H., et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12140-12145.
104. Cao R., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003, 9:604-613.
105. Smits A., et al. Rat brain capillary endothelial cells express functional PDGF B-type receptors. Growth Factors 1989, 2:1-8.
106. Risau W., et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992, 7:261-266.
107. Li X., et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J. Clin. Invest. 2005, 115:118-127.
108. Gerhardt H., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 2003, 161:1163-1177.
109. Hellstrom M., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-780.
110. Ridgway J., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
111. Noguera-Troise I., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
112. Guarani V., et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473:234-238.
113. Hellstrom M., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 2001, 153:543-553.
114. Greenberg J.I., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
115. Guo P., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 2003, 162:1083-1093.
116. Nishishita T., Lin P.C. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J. Cell. Biochem. 2004, 91:584-593.
117. Phelps E.D., et al. Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells. Am. J. Physiol. Cell. Physiol. 2006, 290:C352-C361.
118. Saik J.E., et al. Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogels. Acta Biomater. 2011, 7:133-143.
119. Wang D., et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999, 59:1464-1472.
120. Xue Y., et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med. 2012, 18:100-110.
121. Pardali E., ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front. Biosci. 2009, 14:4848-4861.
122. Cao R., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004, 6:333-345.
123. Bruyere F., et al. Modeling lymphangiogenesis in a three-dimensional culture system. Nat. Methods 2008, 5:431-437.
124. Kodama M., et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci. 2010, 101:1984-1989.
125. Donnem T., et al. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann. Oncol. 2010, 21:223-231.
126. Inoue A., et al. Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol. Int. 2008, 58:611-619.
127. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
128. Cirri P., Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012, 31:195-208.
129. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
130. Forsberg K., et al. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:393-397.
131. Micke P., Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl. 2):163-175.
132. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
133. Shao Z.M., et al. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000, 19:4337-4345.
134. Xing F., et al. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 2010, 15:166-179.
135. Franco O.E., et al. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21:33-39.
136. Crawford Y., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
137. Orimo A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
138. Matsumoto K., Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 2006, 119:477-483.
139. Erez N., et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
140. Murata T., et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011, 71:6633-6642.
141. Martinez-Outschoorn U.E., et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533.
142. Petersen O.W., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 2003, 162:391-402.
143. Radisky D.C., et al. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. J. Cell. Biochem. 2007, 101:830-839.
144. Ostman A., Heldin C.H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 2001, 80:1-38.
145. Campbell J.S., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3389-3394.
146. Kong L.Y., et al. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin. Cancer Res. 2010, 16:5722-5733.
147. Wagsater D., et al. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis 2009, 202:415-423.
148. Kennedy B.C., et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 2009, 10:11.
149. Wang Y.Z., et al. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 2000, 19:2075-2085.
150. Yu H., et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
151. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
152. Kortylewski M., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
153. Gersuk G.M., et al. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms. Scand. J. Immunol. 1991, 33:521-532.
154. Wang Z., et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67:11377-11385.
155. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
156. Johnsson A., et al. Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. Nature 1985, 317:438-440.
157. Motzer R.J., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
158. Davids M.S., et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J. Clin. Oncol. 2009, 27:e97-e100.
159. Escudier B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
160. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. 2005, 16:1702-1708.
161. Reardon D.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 2005, 23:9359-9368.
162. Dresemann G., et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 2010, 96:393-402.
163. Bergers G., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
164. Erber R., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18:338-340.
165. Griffin R.J., et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002, 62:1702-1706.
166. Nisancioglu M.H., et al. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010, 70:5109-5115.
167. Hainsworth J.D., et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a Phase I/II trial. Clin. Genitourin. Cancer 2007, 5:427-432.
168. Liu K.W., et al. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J. Clin. Invest. 2011, 121:905-917.
169. Negri T., et al. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J. Pathol. 2009, 217:103-112.
170. Heinrich M.C., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008, 26:5352-5359.
171. Nishida T., et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int. J. Clin. Oncol. 2009, 14:143-149.
172. Heinrich M.C., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003, 21:4342-4349.
173. Debiec-Rychter M., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 2006, 42:1093-1103.
174. Corless C.L., et al. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 2011, 11:865-878.
175. Chen L.L., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004, 64:5913-5919.
176. Yoshida D., et al. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J. Neurooncol. 2006, 76:13-21.
177. ten Freyhaus H., et al. Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am. J. Respir. Crit. Care Med. 2011, 183:1092-1102.
178. Huang J., et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2004, 2:36-42.
179. Hou X., et al. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12216-12221.
180. Rahbari N.N., et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011, 11:286.